Skip to content
NBlaz – Lifestyle
Author:
NEKTAR THERAPEUTICS
Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting
March 20, 2026
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
March 12, 2026
←
Previous Page
1
2